Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Working Capital Changes (2017 - 2025)

Historic Other Working Capital Changes for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $84000.0.

  • Puma Biotechnology's Other Working Capital Changes rose 10837.49% to $84000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $989000.0, marking a year-over-year increase of 13924.6%. This contributed to the annual value of -$1.0 million for FY2024, which is 3408.04% up from last year.
  • Puma Biotechnology's Other Working Capital Changes amounted to $84000.0 in Q3 2025, which was up 10837.49% from -$1.3 million recorded in Q2 2025.
  • Puma Biotechnology's Other Working Capital Changes' 5-year high stood at $4.7 million during Q2 2022, with a 5-year trough of -$6.0 million in Q4 2022.
  • Moreover, its 5-year median value for Other Working Capital Changes was -$4000.0 (2021), whereas its average is -$227030.3.
  • Over the last 5 years, Puma Biotechnology's Other Working Capital Changes had its largest YoY gain of 240581.98% in 2022, and its largest YoY loss of 15065000.0% in 2022.
  • Puma Biotechnology's Other Working Capital Changes (Quarter) stood at -$4000.0 in 2021, then plummeted by 150650.0% to -$6.0 million in 2022, then skyrocketed by 97.71% to -$138000.0 in 2023, then soared by 1101.45% to $1.4 million in 2024, then plummeted by 93.92% to $84000.0 in 2025.
  • Its last three reported values are $84000.0 in Q3 2025, -$1.3 million for Q2 2025, and $789000.0 during Q1 2025.